Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy
- PMID: 10508191
- DOI: 10.1093/intimm/11.10.1717
Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy
Abstract
Recent reports have demonstrated that feeding small amounts of antigen conjugated to the B subunit of cholera toxin (CTB) suppress immune responses in experimental models of certain T(h)1-based autoimmune diseases. We have established a model of aerosol sensitization leading to T(h)2-mediated allergic immune responses in BALB/c mice. In the present study two different antigens, the dietary antigen ovalbumin (OVA) and the inhalant allergen Bet v 1 (the major birch pollen allergen), chemically coupled to recombinant CTB were tested for their potential to influence T(h)2-like immune responses. Intranasal administration of OVA-CTB prior to sensitization with OVA led to a significant decrease of antigen-specific IgE antibody levels, but a marked increase of OVA-specific IgG2a antibodies as compared to non-pretreated, sensitized animals. Antigen-specific lympho-proliferative responses in vitro were reduced by 65% in the pretreated group; IL-5 and IL-4 production were decreased in responder cells of lungs and spleens of nasally pretreated mice. In contrast, mucosal administration of rBet v 1-CTB conjugates prior to sensitization led to an up-regulation of allergen-specific IgE, IgG1 and IgG2a, increased in vitro lympho-proliferative responses as well as augmented production of IL-5, IL-4, IL-10 and IFN-gamma. Intranasal administration prior to sensitization of unconjugated allergens showed also contrasting effects: OVA could not significantly influence antigen-specific antibody or cytokine production, whereas intranasal pretreatment with unconjugated Bet v 1 suppressed allergen-specific immune responses in vivo and in vitro. These results demonstrated that the two antigens-in conjugated as in unconjugated form-had different effects on the T(h)2 immune responses. We therefore conclude that the tolerogenic or immunogenic properties of CTB-and probably also other antigen-delivery systems-strongly depend on the nature of the coupled antigen-allergen.
Corrected and republished from
-
Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.Int Immunol. 1999 Jul;11(7):1131-8. doi: 10.1093/intimm/11.7.1131. Int Immunol. 1999. Corrected and republished in: Int Immunol. 1999 Oct;11(10):1717-24. doi: 10.1093/intimm/11.10.1717. PMID: 10383946 Corrected and republished.
Similar articles
-
Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.Int Immunol. 1999 Jul;11(7):1131-8. doi: 10.1093/intimm/11.7.1131. Int Immunol. 1999. Corrected and republished in: Int Immunol. 1999 Oct;11(10):1717-24. doi: 10.1093/intimm/11.10.1717. PMID: 10383946 Corrected and republished.
-
Modulation of an allergic immune response via the mucosal route in a murine model of inhalative type-I allergy.Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):129-32. doi: 10.1159/000024048. Int Arch Allergy Immunol. 1999. PMID: 10224359
-
Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice.Clin Exp Allergy. 2000 Jul;30(7):1024-32. doi: 10.1046/j.1365-2222.2000.00849.x. Clin Exp Allergy. 2000. PMID: 10848926
-
Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine.Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):290-4. doi: 10.1159/000237005. Int Arch Allergy Immunol. 1995. PMID: 7613152 Review.
-
Immune tolerance and protection against allergic sensitization.Allergy. 1995;50(25 Suppl):34-6. doi: 10.1111/j.1398-9995.1995.tb04274.x. Allergy. 1995. PMID: 7677232 Review.
Cited by
-
The ABC of clinical and experimental adjuvants--a brief overview.Immunol Lett. 2010 Jan 18;128(1):29-35. doi: 10.1016/j.imlet.2009.10.005. Epub 2009 Nov 4. Immunol Lett. 2010. PMID: 19895847 Free PMC article. Review.
-
Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells.Immunology. 2006 Jul;118(3):311-20. doi: 10.1111/j.1365-2567.2006.02368.x. Immunology. 2006. PMID: 16827892 Free PMC article.
-
Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells.Infect Immun. 2001 Sep;69(9):5716-25. doi: 10.1128/IAI.69.9.5716-5725.2001. Infect Immun. 2001. PMID: 11500448 Free PMC article.
-
Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.Clin Exp Immunol. 2003 Aug;133(2):170-6. doi: 10.1046/j.1365-2249.2003.02210.x. Clin Exp Immunol. 2003. PMID: 12869021 Free PMC article.
-
Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy.Immunology. 2003 Nov;110(3):376-85. doi: 10.1046/j.1365-2567.2003.01751.x. Immunology. 2003. PMID: 14632666 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases